Soy protein hydrolysates significantly enhance cell growth and recombinant protein production in cell cultures. The extent of this enhancement in cell growth and IgG production is known to vary from batch to batch. This can be due to differences in the abundance of different classes of compounds (e.g., peptide content), the quality of these compounds (e.g., glycated peptides), or the presence of specific compounds (e.g., furosine). These quantitative and qualitative differences between batches of hydrolysates result from variation in the seed composition and seed/meal processing. Although a considerable amount of literature is available that describes these factors, this knowledge has not been combined in an overview yet. The aim of this review is to identify the most dominant factors that affect hydrolysate composition and functionality. Although there is a limited influence of variation in the seed composition, the overview shows that the qualitative changes in hydrolysate composition result in the formation of minor compounds (e.g., Maillard reaction products). In pure systems, these compounds have a profound effect on the cell culture functionality. This suggests that the presence of these compounds in soy protein hydrolysates may affect hydrolysate functionality as well. This influence on the functionality can be of direct or indirect nature. For instance, some minor compounds (e.g., Maillard reaction products) are cytotoxic, whereas other compounds (e.g., phytates) suppress protein hydrolysis during hydrolysate production, resulting in altered peptide composition, and, thus, affect the functionality.
Efficient cytosolic delivery with serum-independent kinetics and low toxicity are the ultimate challenges towards the transformation of an antisense oligonucleotide or a therapeutic peptide to a suitable drug candidate for clinical trials. Most delivery vehicles falter on at least one of the above requirements, which hinders their potential in in vivo models as well. Our previous reports on internal guanidinium transporters (IGTs) have established the diversity of this particular class of molecule with the efficient delivery of antisense phosphorodiamidate morpholino oligonucleotides. In this paper, we report twenty IGTs with different types of evidence-backed structural modifications with different types of head-group linkage R, which significantly change the transfection, toxicity, and endosomal escape. Based on these three criteria, the analogues were sorted systematically to find the more promising IGTs, which were then further examined by LysoTracker studies. Finally, two analogues, with cholesteryl linkage (R = Chol) and pentafluorobenzyl linkage (R = PF Cbz), were selected for a proapoptotic peptide delivery as the final validation using a long-chain di-acid linker conjugation. Detailed mechanistic studies also revealed that the primary pathway of endocytosis is macropinocytosis, and that other pathways play different roles depending on the head group of the IGT. Since endocytosis pathways for entry depend on the nature of the cell line, we have shown the mechanistic variations in two cell lines for validation.
The variety of compounds present in chemically defined media as well as media supplements makes it difficult to use a mechanistic approach to study the effect of supplement composition on culture functionality. Typical supplements, such as soy protein hydrolysates contain peptides, amino acids, carbohydrates, isoflavones, and saponins. To study the relative contribution of these compound classes, a set of hydrolysates were produced, containing 58-83% proteinaceous material and 5-21% carbohydrates. While the content of the different compounds classes varied, the composition (e.g., peptide profiles, carbohydrate composition) did not vary in hydrolysates. The hydrolysates were supplemented to a chemically defined medium in cell culture, based on equal weight and on equal protein levels. The latter showed that an increase in the carbohydrate concentration significantly (P value < 0.004) increased integral viable cell density (IVCD) (R = 0.7) and decreased total IgG (R = -0.7) and specific IgG production (R = -0.9). The extrapolation of effects of protein concentration showed that an increase in protein concentration increased total and specific IgG production and suppressed IVCD. In addition to proteins and carbohydrates, the functionality of soy protein hydrolysates may be modulated by the presence of other minor compounds. In the current study, the large differences in the balance between total proteins and total carbohydrates in the supplemented media seem to be a main factor influencing the balance between the viable cell density, total IgG, and specific IgG production.
Cell-penetrating peptides (CPPs) are structurally diverse sophisticated tools endowed with high arginine content, amphipathicity, and well-adopted suitable secondary structures. Despite its capability of breaching the lipid barriers, CPP has major limitations such as in vivo metabolic instability, poor bioavailability, and reduced endosomal escape tendency, which are yet to be improved. In this context, we first have introduced a new class of cellular transporter having a guanidiniumfunctionalized δ-azaproline (δ-azp)-containing peptide where the δ-azp structurally resembles the "proline" amino acid having an additional "N" at the δ-position. This non-natural peptidic backbone was found to impart proteolytic stability, as reported earlier by our group. Herein, we report the synthesis of a flexible azaproline-tetraguanidinium transporter named FAT along with a revised scalable methodology for δ-azp compared to our previously reported procedure. FAT shows a random-coil-like structure as determined by CD spectroscopy, and is hence structurally different from the polyproline PPII helix. Direct translocation is predicted to be the possible mode of the cellular entrance of FAT into CHO cells when the "Bodipy" fluorophore is covalently attached as the cargo. Simultaneously, two other macromolecular therapeutics, e.g., proapoptotic domain peptide (PAD, a 14-mer peptide) and programmed death ligand 1 (PDL1) morpholino (a 25-mer antisense oligo), were successfully conjugated with FAT and delivered into human carcinoma cells, and their efficacy was analyzed by MTT assay and western blot technique, respectively. Having obtained promising results in internalizing different types of cargos, FAT could be envisaged as a potential drug delivery agent as an alternative to natural CPPs for future application.
The present study explored efficient and exclusive analgesic effects of iboga-analogs in formalin-induced mouse via acute pain model. Novel iboga derivatives namely iboga-alcohol, iboga-amide, iboga-methylamide and iboga ester-exo were administered intraperitoneally to evaluate the anti-nociceptive, anti-inflammatory and neuromodulatory effects. Pain assessment was done by paw diameter, paw licking and tail immersion tests. Locomotor activity and anxiety-like behavior were determined by open field test and elevated plus maze. Inflammatory mediators, neurotransmitters and neurotrophic factors were measured from isolated serum, paw tissue and spinal segment. Iboga-analogs significantly reduced paw diameters. Decreased tail flick latency reversed in iboga-alcohol and methyl-amide particularly. Restricted locomotion was also significantly reversed in iboga-alcohol, iboga-amide, and iboga-methyl amide. Anxiolytic behaviour was obtained in the iboga-alcohol, iboga-amide and methyl-amide treated groups. Paw Substance P, CGRP, COX-2 and p65 nuclear translocation; serum IL-6 & TNF-α levels were significantly decreased in the iboga-alcohol treated group. Iboga-alcohol reversed the downregulation of GABA, Dopamine, and elevation of Substance P, NK1R and Glutamate. HRMS analysis confirmed the passage of all iboga-analogs in the brain. Iboga-analogs overturned the depleted BDNF whereas, GDNF elevation was further exaggerated. Taken together, these novel iboga-analogs, particularly iboga-alcohol, executed effective anti-nociception and prevented neuroinflammation. They warrant further clinical applications in acute pain situations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.